Nature genetics · 2026
Spatial analysis of head and neck cancer identifies two ecosystems with distinct modes of epithelial-to-mesenchymal transition.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Simkin Dor, Barrett Thomas F, Zhang Lingling, Moore Michael J, Greenwald Alissa C, Galili Noam, Mints Michael, Ramadan Salma, Yu Victoria, Mullins Riley D Z, Zaretsky Jesse, Bischoff Porter, Adkins Douglas, Thorstad Wade L, Karam Sana D, Paniello Randall C, Rich Jason T, Jackson Ryan S, Pipkorn Patrik, Zolkind Paul A, Peng Guangyong, Harbison R Alex, Chernock Rebecca, Parikh Anuraag S, Puram Sidharth V, Tirosh Itay
Аннотация
Head and neck squamous cell carcinoma (HNSCC) shows substantial intra- and inter-tumoral heterogeneity. We mapped tumor architecture across HPV-positive and HPV-negative HNSCC through spatial transcriptomics (n = 26). HPV-positive tumors display hypercellularity, higher lymphocyte presence, enriched hypoxia and reduced partial epithelial-to-mesenchymal transition (p-EMT) in malignant cells. We observed two distinct spatial architectures of p-EMT: p-EMT edge, where p-EMT is coupled to fibroblasts at the invasive front via TGFβ, and p-EMT core, in which tumor-infiltrating immunosuppressive macrophages and neutrophils induce p-EMT via oncostatin M in the core of tumor nests. These two p-EMT patterns were consistent across multiple samples from the same tumor, suggesting they are tumor-wide features. Together, these findings reveal that distinct interactions in the tumor microenvironment converge on a similar p-EMT cellular phenotype, but in a different spatial pattern that may have potential biological and clinical implications for our understanding of invasion, immune modulation and new targeted therapeutics for HNSCC.